Condition
Cornea Transplant
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Lx201
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
1Total
Phase 3 (1)
Trial Status
Terminated1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06830538RecruitingPrimary
Study of the Anatomical and Functional Recovery and Quality of Life of Patients Undergoing Corneal Transplantation
NCT00447187Phase 3Terminated
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
Showing all 2 trials
Research Network
Common Treatments
- Lx2011
Active Sponsors
- IRCCS Azienda Ospedaliero-Universitaria di Bologna1
- Lux Biosciences, Inc.1
Top Investigators
Chief Medical Officer, Lux Biosciences, Inc.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Related Conditions
- Corneal Diseases1